Compare Merck & Co., Inc. (MRK) vs XP Inc. Class A Common Stock (XP) Price & Performance

Merck & Co., Inc.Trade

XP Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs XP Inc. Class A Common Stock — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while XP Inc. Class A Common Stock trades at $30.27 (market cap $14.99B). The key difference: Merck & Co., Inc. is far larger — about 23.5× XP Inc. Class A Common Stock's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and XP Inc. Class A Common Stock for 0 Days on average.

	MRK	XP
Market Cap	$352.29B	$14.99B
Volume	6,348,796	14,273,752
Sector	Health	Financials
52-Week High	$156.43	$30.21
52-Week Low	$82.49	$14.94
Typical Hold Time	98 Days	0 Days
Enterprise Value	$399.05B	$24.70B
Dividend Yield	2.38%	0.68%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.

XP Inc. Class A Common Stock

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

MRK

Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 17 hours agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 23 hours agoBullish Dutch court blocks Merck's Keytruda SC sales in Europe for patent infringement.PRNewsWire · 1 day agoNeutral View details →

View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About XP Inc. Class A Common Stock

XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.